Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II, Single-Arm Open-Label Study Of The Combination Of Atezolizumab And Bevacizumab In Rare Solid Tumors

Trial Profile

A Phase II, Single-Arm Open-Label Study Of The Combination Of Atezolizumab And Bevacizumab In Rare Solid Tumors

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 16 Oct 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Atezolizumab (Primary) ; Bevacizumab
  • Indications Adenocarcinoma; Anal cancer; Appendiceal cancer; Carcinoma; Cervical cancer; Malignant-mesothelioma; Merkel cell carcinoma; Nasopharyngeal cancer; Neuroendocrine tumours; Pancreatic cancer; Penile cancer; Peritoneal cancer; Solid tumours; Squamous cell cancer; Vulvovaginal cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 12 Oct 2023 Planned End Date changed from 1 Dec 2023 to 30 Jun 2024.
    • 12 Oct 2023 Planned primary completion date changed from 1 Dec 2023 to 30 Jun 2024.
    • 01 Jul 2023 Results (n=20) assessing Biomarkers associated with survival benefit to atezolizumab and bevacizumab for treatment of metastatic anal cancer presented at the 25th World Congress on Gastrointestinal Cancer
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top